Advances in Ovarian Cancer Research: Exploiting Vulnerabilities

An AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poste...
1 downloads 0 Views 100KB Size
An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.

DNA Damage and Homologous Recombination A01 A comparison of the mechanisms and cytotoxic activity of dianhydrogalactitol (VAL-083) to cisplatin in ovarian tumor models harboring wild-type and mutant p53. Jeffrey A Bacha, Michelle Martinez-Rivera, Guanghan He, Xiaolei Xie, Anne Steino, Sarath Kanekal, Dennis M Brown, Zahid H Siddik. A02 CDK6 controls platinum sensitivity via the regulation of FOXO3a/ATR: A new actionable pathway for ovarian cancer patients. Alessandra Dall’Acqua, Schiappacassi Monica, Gustavo Baldassarre. A03 PARP inhibitor nanotherapy for ovarian cancer. Paige Baldwin, Anders Ohman, Jeremy Thong, Shifalika Tangutoori, Daniela Dinulescu, Srinivas Sridhar. A04 DNA double-strand break repair assay in primary cultures of patient-derived ovarian carcinoma xenografts. Federica Guffanti, Julia Kaufmann, Francesca Bizzaro, Francesca Ricci, Monica Ganzinelli, Monica Lupi, Raffaella Giavazzi, Lisa Wiesmüller, Giovanna Damia. A05 BRCA1 promoter hypermethylation loss in recurrent high-grade serous carcinoma. Maria Bisogna, Fanny Dao, Narciso Olvera, Ruben Bacares, Liying Zhang, Douglas A Levine. A06, PR5 Identifying potential targets in Cyclin E-amplified tumors. Kai Doberstein, Alison Karst, Dariush Etemadmoghadam , Paul Jones, Gavin Dunn, William Hahn, David Bowtell, Ronny Drapkin. A07 Homologous recombination mutations and overall survival in high-grade serous, endometrioid, and clear cell ovarian carcinomas. Maria I. Harrell, Matthew J. Maurer, Ethan P. Heinzen, Ming K. Lee, Kimberly R. Kalli, Kathy J. Agnew, Ann L. Oberg, Tom Walsh, Barbara M. Norquist, Lynn C. Hartmann, Scott H. Kaufmann, Elizabeth M. Swisher. A08 Targeting the ATR/CHK1 axis in BRCA1/2 mutant ovarian cancer using an orthotopic patientderived xenograft (PDX) model. Hyoung Kim, Erin George, Eric Brown, Rugang Zhang, Clemens Krepler, Janos Tanyi, Rachel Lee, Mark Morgan, Meenhard Herlyn, Fiona Simpkins. A09 Targeting chemoresistant ovarian malignancies to cytostatic drugs and PARP inhibitors by inhibition of CDK12 kinase activity. Jiri Kohoutek, Marek Svoboda, David Vrabel, Hana Paculova, Marta Dzimkova. A10, PR14 Exploiting synthetic lethality between the MK2 and p53 pathways with nanotechnology to sensitize ovarian cancer to chemotherapy. Yi Wen Kong, Erik C Dreaden, Paula T Hammond, Michael B Yaffe. A11 NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib. Iain A McNeish, Kevin K Lin, James X Sun, Sandra Goble, Amit Oza, Robert L Coleman, Clare L Scott, Gottfried Konecny, Anna V Tinker, David M O'Malley, Rebecca Kristeleit, Ling Ma, James D Brenton, Katherine Bell-McGuinn, Ana Oaknin, Alexandra Leary, Elaina Mann, Heidi Giordano, Roman Yelensky, Mitch Raponi, Elizabeth Swisher.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.

A12 Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG oncology study. Barbara M Norquist, Mark F Brady, Maria I Harrell, Tom D Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Robert A Burger, Susan A Davidson, Robert S Mannel, Paul A DiSilvestro, Heather A Lankes, Nilsa C Ramirez, Mary Claire King, Michael J Birrer, Elizabeth M Swisher. A13 Transferrin facilitates the formation of DNA-double strand breaks via transferrin receptor 1 in fallopian tube epithelial cells. Shogo Shigeta, Masafumi Toyoshima, Kazuyuki Kitatani, Masumi Ishibashi, Toshinori Usui, Nobuo Yaegashi. A14, PR02 Identification of germline and somatic alterations in homologous recombination pathway genes in high grade ovarian carcinomas and response to the PARP inhibitor rucaparib in ARIEL2. Elizabeth Swisher, Clare Scott, Kevin K Lin, Maria Harrell, James X Sun, Sandra Goble, Amit M Oza, Robert L Coleman, Gottfried Konecny, Anna Tinker, David M O’Malley, Rebecca Kristeleit, Ling Ma, James Brenton, Katherine Bell-McGuinn, Ana Oaknin, Alexandra Leary, Elaina Mann, Heidi Giordano, Roman Yelensky, Mitch Raponi, Iain McNeish. A15 The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to poly ADP ribose polymerase inhibitors via E2F1 downregulation. Andrew J Wilson, Jeanette Saskowski, Dineo Khabele.

Molecular Drivers of Ovarian Cancer (other than p53) A16 Regulation of TRAIL and NF-kappaB pathways in ovarian cancer. Mariam Anees, Umaima Batool, Sidra Bukhari, Sohail Yousaf. A17 The effects of atypical PKC inhibitors ICA-1 and ACPD on ovarian cancer cell proliferation, RNA levels and atypical PKC levels. Christopher A Apostolatos, Minjel n/a Shah, Andre H Apostolatos. A18 Targeting the Wnt-β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Rebecca C Arend, Jonathan Boone, Sara J Cooper, Austin Gilchrest, Denise K Oelschlager, William E Grizzle, William E Grizzle, Gerald McGwin, Abhishek Gangrade, Michael Straughn, Donald J Buchsbaum. A19 Cytoplasmic ARID1A and poor outcome in ovarian cancer patients. Nicholas W Bateman, Kevin A Byrd, Kelly A Conrads, Carl Morrison, Kunle Odunsi, Chad A Hamilton, G. Larry Maxwell, Thomas P Conrads. A20 Short-form Ron kinase as a novel therapeutic target in ovarian cancer. Magdalena Bieniasz, Alana L Welm. A21 Ovarian tumor cells' adhesion and cell signaling pathways are regulated by ARID3B. Alexander S Bobbs, William Morgan Hallas, Karen D Cowden Dahl.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.

A22 Direct upregulation of STAT3 by miR551b in ovarian cancer. Pradeep Chaluvally-Raghavan, Kang Jin Jeong, Sunila Pradeep, Yiling Lu, Anil Sood, Gordon Mills. A23 The dual roles of microRNA-200: From inclusion cyst formation to cell migration. Pui Wah Choi, Junzheng Yang, Wing Ping Fong, Ross S Berkowitz, William R Welch, Gregory J Goodall, Shu Wing Ng. A24 Hypoxia signaling pathway plays a role in ovarian cancer chemoresistance. Noelle L Cutter, Tyler Walther, Liam Gallagher, Robert Lucito, Kazimierz Wrzeszczynski. A25 BRAFV600E mutations in serous ovarian cancer and response to the BRAF inhibitor, dabrafenib. Anna DeFazio, Tania Moujaber, Dariush Etemadmoghadam, Catherine Kennedy, Yoke-Eng Chiew, Rosemary L Balleine, Catherine Saunders, Gerard V Wain, Alexander Dobrovic, Australian Ovarian Cancer Study Group (AOCS), David DL Bowtell, Paul R Harnett. A26 Levels of phospho-Connexin 43 and phospho-TRKB in epithelial ovarian cancer. Maritza P Garrido, Alberto Selman, Fernando Gabler, Margarita Vega, Carmen Romero. A27 Transcriptome analyses of human ampulla and fimbriae highlight similarities and differences. Sophia George, Anca Milea, Sowamber Ramlogan , Michael Considine, Leslie Cope, Noor Salman, Patricia Shaw. A28 Osteopontin splicing isoforms expression is modulated by partial epithelial mesenchymal transition in ovarian carcinoma cells. Ingridy Celestino, Isabella S. Guimarães, Leticia B. A. Rangel, Etel R. P. Gimba. A29 YAP interacts with the ERBB signaling pathway to control ovarian surface epithelial cell tumorigenesis. chunbo he, Xiangmin LV, John S Davis, Wang Cheng. A30 Frizzled-7 (FZD7)-mediated non-canonical Wnt-Planar Cell Polarity (PCP) signaling pathway as a novel molecular driver for the C5/Proliferative/Stem-A molecular subtype of ovarian cancer. Mohammad Asad, Meng Kang Wong, Tuan Zea Tan, David Virshup, Jean Paul Thiery, Ruby Yun-Ju Huang. A31 High-grade serous ovarian cancer subtyping identifies pathways for targeted therapy. Kaisa Huhtinen, Ping Chen, Katja Kaipio, Piia Mikkonen, Viljami Aittomäki, Rony Lindell, Johanna Hynninen, Annika Auranen, Seija Grenman, Rainer Lehtonen, Sampsa Hautaniemi, Olli Carpén. A32 PBX1, a transcriptional regulator, promotes stemness and chemoresistance in ovarian cancer. Jin-Gyoung Jung, Tae-Hoen Kim, Emily Gerry, Jen-Chun Kuan, Ayse Ayhan, Ben Davidson, Ie-Ming Shih, Tian-Li Wang. A33 Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcemic type. Anthony N Karnezis, Yemin Wang, Pilar Ramos, William Hendricks, Holly Yin, Esther Oliva, Emanuela D’Angelo, Jaime Prat, Marisa R Nucci, Torsten O Nielsen, Bernard E Weissman, Jeffrey M Trent, C Blake Gilks, David G Huntsman.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.

A34 Activation-induced cytidine deaminase links ovulation-induced inflammation and serous carcinogenesis. Stav Sapoznik, Keren Bahar-Shany, Hadar Brand, Yishay Pinto, Orshay Gabay, Efrat GlickSaar, Chen Dor, Oranit Zadok, Iris Barshack, Adi Zundelevich, Einav Nili Gal-Yam , Yuval Yung, Ariel Hourvitz, Jacob Korach, Mario Beiner, Jasmine Jacob, Erez Y Levanon, Michal Barak, Sarit Aviel-Ronen, Keren Levanon. A35 Elucidating mechanisms involved in long-term response to platinum-based chemotherapy in high-grade serous ovarian cancer. Stephanie Lheureux, Cindy Yang, Patricia Shaw, Blaise Clarke, Julissa Tsao, Katherine Karakasis, Marcus Butler, Noor Salman, Mark Dowar, Jing Xu, Laurent Poulain, Pamela S Ohashi, Trevor Pugh, Amit Oza. A36, PR18 Survival of ARHI-induced dormant autophagic cell death in vivo requires permissive levels of VEGF, IL-8 and IGF-1 in the tumor microenvironment. Zhen Lu, Aaron F Orozco, Hailing Yang, Margie N Sutton, Yan Wang, Weiqun Mao, Douglas A Levine, Robert C Bast, Robert C Bast. A37 Yes-associated protein 1 (YAP) in the growth and tumorigenesis of ovarian granulosa cells. Xiangmin Lv, Chunbo He, Guohua Hua, Jixin Dong, John S Davis, Cheng Wang. A38 Identification through functional genomics screening of factors whose downregulation enhances the side population in ovarian cancer. Noriomi Matsumura, Koji Yamanoi, Susan K Murphy, Junzo Hamanishi, Kaoru Abiko, Ken Yamaguchi, Tsukasa Baba, Masafumi Koshiyama, Ikuo Konishi. A39 FOXO1 is a key determinant of progesterone receptor isoform-specific senescence programming in ovarian cancer cells. Caroline H Diep, Todd P Knutson, Laura J Mauro, Carol A Lange . A40 Regulation of PAX2 in fallopian tube epithelium and high-grade serous ovarian carcinoma. Dimple Ashok Modi, Rosemarie D Tagare, Joanna E Burdette. A41 The heat shock transcription factor HSF1 induces ovarian cancer epithelial-mesenchymal transition in a 3-D spheroid growth model. Trillitye Paullin, Chase Powell, Menzie Christopher, Robert Hill, Christopher Martyniuk, Sandy Westerheide. A42 TWIST1 as a driver of accelerated tumor growth and drug resistance: Potential novel pathways and therapeutics. Cai M Roberts, Michelle A Tran, James Finlay, Sophia Allaf Shahin, Joana Loeza, Leslie Cisneros, Emily Ye, Thanh Dellinger, Carlotta A Glackin. A43 DIRAS1 and DIRAS2 are tumor suppressor candidates that inhibit cell growth, motility, and proliferation while regulating autophagy in ovarian cancer. Margie N Sutton, Zhen Lu, Robert C Bast. A44 Clinical value of immunohistochemical expression of EGFL7 within high-grade serous ovarian cancer tissue. Jacek Jan Sznurkowski, Anton Zawrocki, Maciej Pawlowski. A45 Proteins involved in the Calreticulin translocation pathway are altered in human ovarian cancer samples. Carolina Vera, Paula García, Alberto Selman, Fernando Gabler, Margarita Vega, Arturo Ferreira, Carmen Romero.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.

A46 Targeting transcriptional networks for ovarian cancer therapy. Sarah R Walker, Yixi Zhang, Katarina Bartel, Yasmin Kroll, David A Frank. A47 TGF-β inhibitors reduce ovarian cancer cells proliferation, migration, and invasion in vitro. Qing Zhang, William A. Cliby.

Immunotherapy for Ovarian Cancer A48 Ovarian tumor-induced immunosuppression of NK cells and its prevention by dietary supplementation of herbal Withaferin A (Ashwagandha). Animesh Barua, Pincas Bitterman, Sameer Sharma, Sanjib Basu, Janice M Bahr. A49 Investigating the expression of inhibitory surface molecules in ovarian cancer tumorinfiltrating lymphocytes. Jessica Chacon, Tori Yamamoto, Thomas Garrabrant, Gabor Kari, Andrew Best, Qunrui Ye, Daniel Powell. A50 Chemoimmunotherapy with PD-1 blockade and paclitaxel induce a potent antitumor immunity in ovarian cancers. Junzo Hamanishi, Jin Peng, Noriomi Matsumura, Kaoru Abiko, Tsukasa Baba, Ken Yamaguchi, Ikuo Konishi, Masaki Mandai. A51, PR03 Combinatorial blockade of PD-1, CTLA-4, and LAG-3 pathways inhibits murine ovarian tumor growth. Ruea-Yea Huang, AJ McGray, Kunle Odunsi. A52 Efficacy of specified natural killer (NK) cells in ovarian cancer xenograft models. Young Jae Lee, Ha Young Lee, Yu Kyung Hwang, Kyung Jin Lee, Shin Wha Lee, Yong Man Kim. A53 Combining oncolytic virotherapy with immunotherapy for ovarian cancer treatment. AJ Robert McGray, Cheryl Eppolito, Kyle Stephenson, Jonathan Pol, Brian Lichty, Kunle Odunsi. A54 Regulating MUC16 expression to decrease ovarian tumor proliferation and increase efficacy of therapeutic antibodies. Mildred Felder, Arvinder Kapur, Ryan Serbin, San Zheng, May Xiong, Norishige Yamada, Manish Patankar. A55, PR04 Epigenetic treatment of ovarian cancer cells increases immune cell recruitment to the tumor microenvironment: Implications for response to immune checkpoint therapy. Meredith Stone, Katherine Chiappinelli, Huili Li, Lauren Murphy, Dimitris Mathios, Michael Lim, Stephen Baylin, Cynthia Zahnow. A56 Inhibition of Snail-induced EMT promotes anti-tumor immune response in ovarian cancer. Mana Taki, Kaoru Abiko, Noriomi Matsumura, Tsukasa Baba, Junzo Hamanishi, Naoki Horikawa, Ikuo Konishi. A57 Platinum induces IL-6-signaling mediated activation of ALDH1A1 and enriches the cancer stem cell population in ovarian cancer. Yinu Wang, Anirban Kumar Mitra, Kenneth P Nephew.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.

A58 Bispecific anti-CD3-folate for the treatment of ovarian cancer. Jinming Xia, Kristine deDios, Evelyn Rodrigo, Robin Humphreys, Alan Wahl, Marco Gymnopoulos. A59 PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer. Shannon Grabosch, Feitianzhi Zeng, Lixin Zhang, Mary Strange, Joan Brozick, Robert P Edwards, Anda Vlad.

Other A60 DNA copy-number alterations in primary ovarian serous cystadenocarcinoma encoding for cell transformation and predicting survival and response to platinum therapy throughout the course of the disease. Orly Alter. A61 Detection of ovarian cancer micrometastasis using nanoparticle-delivered probe targeted towards tumor-associated neovasculature. Ayesha Alvero, Eydis Lima, Dongin Kim, Sean Orton, Mary Pitruzzello, Yang Yang-Hartwich, Dan-Arin Silasi. A62 TRX-1 targets chemoresistant tumor-initiating cells and prolongs survival in a recurrent ovarian cancer animal model. Ayesha Alvero, Eydis Lima, Mary Pitruzzello, Yang Yang-Hartwich, David Brown, Andrew Heaton, Gil Mor.

Prevention, Screening, Early Diagnostics, and Epidemiology A63 The importance of cyclooxygenase 1 and 2 expression in ovarian cancer survival: Notable differences by histologic subtype. Alicia Beeghly-Fadiel, Meral El Ramahi, Andrew Wilson, Spencer Keene, Oluwole Fadare, Marta A. Crispens, Dineo Khabele.

Other A64 β-catenin as a TIC therapeutic target in epithelial ovarian cancer. Anil Belur Nagaraj, Peronne Joseph, Olga Kovalenko, Sareena Singh, Amy Armstrong, Analisa DiFeo. A65

Nodal contributes to cisplatin resistance in ovarian cancer cells. Olena Bilyk.

Modeling Systems for Ovarian Cancer A66 The CD73+/CD24- subpopulation of ovarian cancer cells is enriched in cancer stem cells. Michela Lupia, Giovanni Bertalot, Pier Paolo Di Fiore, Nicoletta Colombo, Fabrizio Bianchi, Ugo Cavallaro.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.

Other A67 Impact of estrogen on the response of ovarian tumor cells to cisplatin. Georgina Cheng, Carly Galimanis , Heidi Baumgartner Wilson , Kian Behbakht. A68 Sphingosine kinase 1 as a mediator and predictor of metformin’s protective effect in ovarian cancer. Tatsuyuki Chiyoda, Xiaojing Liu, Ernst Lengyel, Jason Locasale, Iris Romero. A69 The PAX8 cistrome in benign and malignant Mullerian epithelia. Kevin M Elias, Megan Emori, Myles Brown, Ronny Drapkin. A70 Epigenome and genome alterations in platinum resistant ovarian tumors. Fang Fang, Horacio Cardenas, Dave Miller, Aaron Buechlein, Qing Yu, Yunlong Liu, Guanglong Jiang, Pietro Taverna, Harold Keer, Doug Rusch, Daniela Matei, Kenneth P Nephew.

Ovarian Cancer Tumor Microenvironment A71 The receptor tyrosine kinase, AXL, is a therapeutic target driving the mesenchymal phenotype in ovarian cancer. Katherine C Fuh, Laura Divine, Michaela Soriano, Colleen Wu, Anh Diep, Andrew Loza, Anne Gibson, Adam Krieg, Amato Giaccia, Erinn Rankin.

Other A72 Dissecting the role of NF-kappaB signaling in ovarian cancer tumor-initiating cells. Carrie D House, Christina M Annunziata. A73 CDK4/6 inhibition as maintenance therapy in ovarian cancer. Mangala Iyengar, Lan Coffman, Ronald Buckanovich. A74 Proteasome subunit RPN13 as a candidate target for treatment of ovarian carcinoma. Rosie T Jiang, Ravi K Anchoori, Anna V Yemelyanova, Chien-fu Hung. A75 Big data and computational biology method for personalized prognosis of high grade serous ovarian carcinoma. Ghim Siong Ow, Zhiqun Tang, Anna Vladimirovna Ivshina, Vladimir Andreevich Kuznetsov. A76 Targeting phosphodiesterase 10A for chemoprevention and treatment of ovarian cancer. Luciana Madeira da Silva, Elaine Gavin, Kevin Lee, Ileana Aragon, Veronica Ramírez-Alcántara, Jennifer Scalici, Rodney P Rocconi, Gary A Piazza.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session A – Sunday, October 18, 2015, 5:30 p.m.-7:30 p.m.

A77 Validation of the EORTC QLQ-OV28 instrument for the assessment of quality of life in women with ovarian carcinoma in Mexico. Dolores Gallardo-Rincon, Wendy Munoz-Montano, David Cantu de Leon, Jaime Coronel-Martinez, Flavia Morales, Luis F Onate-Ocana.

Ovarian Cancer Tumor Microenvironment A78 Serum metabolomics, cytokine measurements, and tumor RNA-seq identified phospholipids correlated with a molecular subclass as strong predictor for outcome in high grade serous ovarian cancer. Stefanie Aust, Anna Bachmayr-Heyda, Katharina Auer, Nyamdelger Sukhbaatar, Samuel M. Meier, Christopher Gerner, Dietmar Pils.

Other A79 Thioxodihydroquinazolinone small molecules that sensitize ovarian cancer stem cells to platinum therapy. Wei Qian, Jing Ma, Peter Wipf, Bennett Van Houten. A80 NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in ovarian cancer (OVCA). Alice Laschuk Herlinger, Min Gao, Ren-Chin Wu, Tian-Li Wang, Leticia B A Rangel, Ie-Ming Shih. A81 Targeting of free fatty acid signaling in ovarian cancer may serve as a potential therapeutic approach. Adnan Munkarah, Suhail Hamid, Jasdeep Chhina, Ismail Mert, LaToya Jackson, Sharon HensleyAlford, Dhananjay Chitale, Shailendra Giri, Ramandeep Rattan . A82 Ovarian cancer cells hijack immune functions of omental milky spots for metastatic colonization. Venkatesh Krishnan, Kelly Mitchell, Jason Miska, Sophia George, Patricia Shaw, Victoria Seewaldt, Maciej Lesniak, Marina Chekmareva, Lev Becker, Vinita Parkash, Cindy Miranti, Carrie RinkerSchaeffer. A83 Profiling potent, novel protein tyrosine phosphatase 4A3 small molecule inhibitors for ovarian cancer. Elizabeth R. Sharlow, Joseph M. Salamoun, Kelley E. McQueeney, Sophie Lewandowski, Jennifer Bryant, Alex Cheung, Paula Pekic, Charles N. Landen, Peter Wipf, John S. Lazo.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.

Molecular Drivers of Ovarian Cancer: p53 B01 Mutagenic and tumorigenic effects of follicular fluid in the context of p53 loss: Initiation of fimbria carcinogenesis. Tang-Yuan Chu, Hsuan-Shun Huang, Che-Fang Hsu. B02 Oxidized hemoglobin promotes survival of ROS-stressed and DNA damaged fallopian tube epithelial cells with p53 loss, resulting in a copy number variation phenotype of HGSC. Hsuan-Shun Huang, Che-Fang Hsu, Tang-Yuan Chu. B03, PR12 Mutant p53 drives early events in fallopian tube tumorigenesis through mesenchymeassociated autocrine production of matrix that supports survival and mesothelial intercalation. Marcin P Iwanicki, Hsing-Yu Chen, Ioannis Zervantonakis, Marian Novak, Taru Muranen, Tan A Ince , Ronny Drapkin , Joan S Brugge. B04 Early detection of ovarian cancer recurrence using p53-mutated circulating tumor DNA as non-invasive biomarkers. Ha-Young Lee, Shin-Wha Lee, Geum-Hee Na, Sang-Eun Lee, Dong-Woo Kang, Yong-Man Kim. B05 Assessment of TP53 mutation status in primary high-grade serous ovarian cancer and cell line models: Comparison between immunohistochemistry and next generation sequencing. Alexander J Cole, Trisha Dwight, Ying Zhu, Anthony J Gill, Kristie-Ann Dickson, Adele Clarkson, Gregory B Gard, Jayne Maidens, Susan Valmadre, Roderick J Clifton-Bligh, Deborah J Marsh. B06, PR13 A designed inhibitor of p53 self-aggregation rescues p53 tumor-suppression function in high-grade serous ovarian carcinoma. Alice Soragni, Deanna M Janzen, Lisa Johnson, Anne G Lindgren, Anh TQ Nguyen, Ekaterina Tiourin, Angela B Soriaga, Jing Lu, Lin Jiang, Kym F Faull, Matteo Pellegrini, Sanaz Memarzadeh, David S Eisenberg.

Non-Serous Ovarian Cancer B07, PR7 Synchronous ovarian and endometrial carcinomas: The case for pseudo-metastasis. Michael S Anglesio, Yi Kan Wang, Madlen Maassen, Hugo M Horlings, Ali Bashashati, Blake Gilks, Stefan Kommoss, David G Huntsman. B08 Genomics analyses of less common epithelial ovarian cancer subtypes. Kylie L Gorringe, Matthew Wakefield, Sally M Hunter, Georgina L Ryland, Dane Cheasley, Michael S Anglesio, Michael Christie, Raghwa Sharma, Antill Yoland, Simone M Rowley, Jason Li, Blake Gilks, Prue E Allan, Andrew N Stephens, Sumi Ananda, Jan Pyman, Martin Koebel, Jessica McAlpine, Charlie Gourley, David G Huntsman, Anna deFazio, David DL Bowtell, Ian G Campbell, Clare Scott. B09 Roles of iASPP, PLK1 and autophagy in ovarian clear cell carcinoma. Ka Kui Chan, Gee Wan Oscar Wong, Kar Loen Karen Chan , Nga Yin Annie Cheung.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.

B10 FOXL2 402C>G mutation can be identified in the circulating tumor DNA of patients with adult-type granulosa cell tumor. Anniina Färkkilä, Melissa K McConechy, Winnie Yang, Aline Talhouk, Ying Ng, Ryan Morin, Annika Riska, Jessica N McAlpine, Leila Unkila-Kallio, Mikko Anttonen, David G Huntsman. B11 Mutational heterogeneity in non-serous ovarian cancers. Jaime Teer, Sean Yoder, Anxhela Gjyshi, Chaomei Zhang, Alvaro Monteiro. B12 Targeted sequencing of ovarian clear cell carcinomas reveals intertumor heterogeneity and distinct clustering related to mutational load. Jenny-Maria Jönsson, Nicolai Skovbjerg Arildsen, Anna Ebbesson, Sofia Westbom-Fremer, Anna Måsbäck, Susanne Malander, Mef Nilbert, Ingrid Hedenfalk. B13 Discovery of novel subtype-specific ovarian cancer biomarkers via integrated tissue proteomics. Felix Leung, Marcus Q Bernardini, Blaise Clarke, Marjan Rouzbahman, Eleftherios P Diamandis, Vathany Kulasingam. B14 Molecular characterization of mucinous ovarian carcinoma. Brooke Schlappe, Jennifer J Mueller, Narciso Olvera, Fanny Dao, Cyriac Kandoth, Faina Bogomolniy, Agnes Viale, Kety Huberman, Gouri Nanjangud, Yaser Hussein, Barry Taylor, Robert Soslow, Douglas A Levine. B15 Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. Jill H Tseng, Petar Jelinic, Brooke A Schlappe, Niamh Conlon, Narciso Olvera, Fanny Dao, Jennifer J Mueller, Yaser Hussein, Robert A Soslow, Douglas A Levine. B16 Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated ovarian cancers. Benjamin Bitler, Ie-Ming Shih, Rugang Zhang.

Prevention, Screening, Early Diagnostics, and Epidemiology B17 Type 2 diabetes, metformin, and ovarian cancer survival: An analysis of tumor registry and electronic medical record data. Spencer Keene, Samantha P. Stansel, Leshaun Clayton, Min Jiang, Melinda Aldrich, Hua Xu, Jeremy Warner, Joshua Denny, Dineo Khabele, Alicia Beeghly-Fadiel. B18 Prediagnostic physical inactivity and epithelial ovarian cancer risk and mortality: Evidence from the Ovarian Cancer Association Consortium. Rikki A Cannioto, Michael LaMonte, Ovarian Cancer Association Consortium (OCAC), Kirsten B Moysich. B19, PR16 Computational modeling of serous ovarian carcinoma dynamics: Implications for screening and therapy. Shengqing Gu, Stephanie Lheureux, Azin Sayad, Liat Hogen Ben-David, Iryna Vyarvelska, Paulina Cybulska, Marcus Bernardini, Barry Rosen, Amit Oza, Benjamin G Neel. B20 Uptake and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. Gillian Hanley, Jessica McAlpine, Leigh Pearce.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.

B21 BRCA mutation status is not associated with better long-term survival from epithelial ovarian cancer. Joanne Kotsopoulos, Isabel Fan, John McLaughlin, Barry Rosen, Taymaa May, Harvey Risch, Ping Sun, Steven Narod. B22 Exploring the effects of incomplete pregnancies on risk of ovarian cancer. Alice W Lee, Celeste Leigh Pearce, Malcolm C Pike, Anna H Wu. B23, PR10 Detection of Müllerian duct carcinomas by lavage of the uterine cavity and mutation analysis – A new concept. Elisabeth Maritschnegg, Yuxuan Wang, Nina Pecha, Reinhard Horvat, Els Van Nieuwenhuysen, Ignace Vergote, Jalid Sehouli, Isaac Kinde, Luis A Diaz, Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein, Robert Zeillinger, Paul Speiser. B24 Personal history of endometriosis and survival in ovarian cancer patients: A pooled analysis of 10 studies from the Ovarian Cancer Association Consortium. Albina N Minlikeeva, Jo L Freudenheim, C. Leigh Pearce, J.Brian Szender, Ovarian Cancer Association Consortium, Kirsten B Moysich. B25 Preclinical evaluation of radiolabeled MUC16 antibodies for PET imaging of epithelial ovarian carcinoma. Brandon E Nemieboka, Dharmarao Thapi, Ariana Bitton, Jason S Lewis. B26 Cell surface expression of CD44v8-10 is associated with good prognosis while cleaved extracellular domain is a marker of poor prognosis in high-grade serous epithelial ovarian cancer. David Pepin, Amanda Sosulski, Heiko Horn, Lihua Zhang, Caroline Coletti, vinod Vathipadiekal, Cesar M Castro, Michael J Birrer, Osamu Nagano, Hidekuyi Saya, Kasper Lage, Patricia K Donahoe. B27 Investigation of small GTPase genes in epithelial ovarian cancer. Hui-Yi Lin, Yin Xiong, Jonathan Tyrer, Douglas C Marchion, Alvaro NA Monteiro, Andrew Berchuck, Joellen M Schildkraut, Ellen L Goode, Susan J Ramus, Simon A Gayther, Paul DP Pharoah, Steven A Narod, Thomas A Sellers, Catherine M Phelan. B28 Validation of a combined 13 gene six protein blood signature for earlier detection of ovarian cancer. Anna Bachmayr-Heyda, Stefanie Aust, Katharina Auer, Peter Borossay, Nina Pecha, Ugo Cavallaro, Ioana Braicu, Sarah Igidbashian, Costanza Savino, Franchi Dorella, Jalid Sehouli, Sonia Zaafrani, Florian Fitzal, Christian Singer, Michael Gnant, Robert Zeillinger, Dietmar Pils. B29 Pre- and post-diagnosis analgesic use and ovarian cancer survival. Elizabeth M Poole, Megan S Rice, Shelley S Tworoger. B30

Dietary fat intake and ovarian cancer risk. Megan Rice, Shelley Tworoger.

B31 Circulating periostin as a potential biomarker to predict platinum-resistant epithelial ovarian cancer. Lisa Ryner, Amy Noyes, Denise Nazzal, Paul Vu, Yinghui Guan, Shan Lu, Alyssa Morimoto, Sue Brignoli, Yulei Wang. B32 Serum calcium and serum albumin can discriminate malignant from benign pelvic masses. Gary G Schwartz, Michael G Kelly, Stuart S Winkler, Samuel S Lentz, Steve H Berliner , Melissa F Swain, Halcyon G Skinner.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.

B33 Reproductive and hormonal risk factors in relation to ovarian cancer survival and platinum resistance. Amy L Shafrir, Ana Babic, Rulla M Tamimi, Bernard A Rosner, Shelley S Tworoger, Kathryn L Terry. B34 Tandem Mass Tag 10-plex isobaric labeling of Pap test proteins: A novel method for the identification of ovarian cancer protein biomarkers by mass spectrometry. Amy P.N. Skubitz, Somi Afiuni, Kristin L.M. Boylan, Melissa Geller, Peter Argenta, Samantha Hoffman, Timothy Griffin. B35 Ovarian cancer incidence projections in the United States: Expected increases through 2030. Sherri L Stewart, Trevor D Thompson, Hannah K Weir, Sun Hee Rim. B36 In vivo laser-based imaging of the human fallopian tube for future cancer detection. Elizabeth M. Swisher, C. David Melville, Richard S Johnston, Kathy Agnew, Seine Chiang, Eric J Seibel. B37 Menstrual cycle characteristics, PCOS, and ovarian cancer risk. Holly R Harris, Linda J Titus, Daniel W Cramer, Kathryn L Terry. B38, PR11 Prediagnosis adiposity, physical activity, and ovarian cancer survival. Adetunji T Toriola, Kathleen Keogan, Leavitt Morrison, Lisa Pollack, Sara Gerhlert, Yikyung Park, Louise Brinton. B39 Serum estrogen and estrogen metabolites and risk of ovarian cancer among postmenopausal women in the Women’s Health Initiative Observational Study. Britton Trabert, Garnet L. Anderson, Louise A. Brinton, Roni T. Falk, Barbara J. Fuhrman, Margery L. Gass, Lewis H. Kuller, Ruth Pfeiffer, Sarunas Sliesoraitis, Howard D. Strickler, Xia Xu, Nicolas Wentzensen. B40 Pre-diagnosis leukocyte telomere length and risk of ovarian cancer. Meng Yang, Jennifer Prescott, Elizabeth M Poole, Megan S Rice, Annika Idahl, Eva Lundin, Immaculata De Vivo , Shelley S Tworoger. B41 Methylation profiling of ovarian cancer to study etiologic and prognostic heterogeneity and to develop a molecular classifier. Clara Bodelon, Keith Killian, Joshua Sampson, Holly Stevenson, William Anderson, Rayna Matsuno, Louise Brinton, Jolanta Lissowska, Mark Sherman, Nicolas Wentzensen. B42 Identification of nucleic acid aptamers for ovarian cancer biomarkers using multiple selection modes and high-throughput sequencing. Rebecca J Whelan, Arvinder Kapur, Mildred Felder, Jamie Shallcross, Manish S Patankar.

Modeling Systems for Ovarian Cancer B43 Characterization of ovarian cancer cells as in vivo models for preclinical studies. Lidia Hernandez, Marianne K Kim, L Tiffany Lyle, Patricia S Steeg, Christina M Annunziata.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.

B44, PR08 Evidence for extra-ovarian origin and peritoneal metastases that precede ovarian carcinomas in high-grade serous ovarian cancer. Jeremy Chien, Viji Shridhar, Andrea Mariani. B45 Chu.

Characterization of human fallopian tube epithelial stem-like cells. Dah-Ching Ding, Tang-Yuan

B46 Use of a novel orthotopic ovarian cancer transplant patient derived xenograft model as a preclinical platform for bench to bedside research. Erin George, Hyoung Kim, Clemens Krepler, Janos Tanyi, Zhi Wei, Katrin Sproesser, Patricia Brafford, Marilda Beqiri, Adina-Monica Vultur, Rachel Lee, Mark Morgan, Ronny Drapkin, Tan Ince, Meenhard Herlyn, Fiona Simpkins. B47 Novel integrative approach to identify therapy sensitive and insensitive ovarian cancer patients. Ping Chen, Kaisa Huhtinen, Katja Kaipio, Piia Mikkonen, Viljami Aittomaki, Rony Lindell, Johanna Hynninen, Annika Auranen, Seija Grenman, Rainer Lehtonen, Olli Carpén, Sampsa Hautaniemi. B48 Design of effective combination therapies for high-grade serous ovarian cancer using patientderived xenograft models. Claudia Iavarone, Ioannis Zervantonakis, Hsing-Yu Chen, Sangeetha S Palakurthi, Joyce Fu Liu, Ursula A Matulonis, Ronny I Drapkin, Gordon B Mills, Joel D Leverson, Deepak Sampath, Joan S Brugge. B49

Giant cancer stem cells of high grade ovarian serous carcinoma. Jinsong Liu.

B50 Anti-neoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models. Caroline C Nitschmann, Rachel M Hurley, Marc A Becker, Xiaonan Hou, Ute Hoch, Thomas C Harding, Deborah H Charych, Scott H Kaufmann, Paul Haluska, Saravut J Weroha . B51 Stress management: LKB1 controls growth and survival of dormant epithelial ovarian cancer spheroid cells. Trevor G Shepherd, Yudith Ramos Valdes, Teresa Peart, Meera Shah, Gabriel E DiMattia. B52 The epithelial-mesenchymal transition factor Snail represses the tumor suppressor microRNA let-7 and contributes to invasiveness of ovarian cancer cells. Yevgeniya Ioffe, Alyse Hill, Michael McCarthy, Linda Sanderman, Hugo Campos, Tise Suzuki, Andrew Caster, Juli Unternaehrer-Hamm. B53 CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer. Josephine Walton, Suzanne Dowson, Darren Ennis, Elaine Leung, Malcolm Farquharson, David Stevenson, Karen Blyth, Douglas Strathdee, Frances R Balkwill, Michelle Lockley, Iain A McNeish.

Ovarian Cancer Tumor Microenvironment B54 Single and collective cell dissemination modes in ovarian cancer. Sara Al-Habyan, Joseph Szymborski, Patricia Tonin, Luke McCaffrey.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.

B55 Peritoneal tumor spread in high grade serous ovarian cancer: Differences in the immune response. Katharina Auer, Anna Bachmayr-Heyda, Nyamdelger Sukhbaatar, Stefanie Aust, Christoph Grimm, Reinhard Horvat, Dietmar Pils. B56 Peritoneal tumor spread in high grade serous ovarian cancer: An effect of the competing endogenous RNA network? Anna Bachmayr-Heyda, Katharina Auer, Nyamdelger Sukhbaatar, Stefanie Aust, Simon Deycmar, Agnes T. Reiner, Stephan Polterauer, Sabine Dekan, Dietmar Pils. B57 Sucrose nonfermenting 1-related kinase (SNRK) expression and function in ovarian cancer. Erin A Bishop, Stephanie M Cossette, Ramani Ramchandran. B58 Functional analysis of the cell adhesion molecule Nectin-4 in the unique tumor microenvironment of ovarian cancer. Kristin L.M. Boylan, Petra C. Buchanan, Dip Shukla, Melissa DeRycke, Bruce Walcheck, Amy P.N. Skubitz. B59 The adhesion molecule L1: A new driver in ovarian cancer vasculature. Francesca Angiolini, Elena Magrini, Pier Paolo Di Fiore, Ugo Cavallaro. B60 Identification of an ovarian tumor:stromal HH:BMP4 signaling loop critical to ovarian cancer growth and chemotherapy resistance. Lan G Coffman, Yunjung Choi, Karen Mclean, Marina Pasca di Magliano, Benjamin Allen, Ronald J Buckanovich. B61 Leptin induces a pro-inflammatory macrophage-cancer cell reinforcement loop that favors high-grade serous ovarian cancer progression among overweight/obese women. Mauricio A Cuello, Lorena Abarzua-Catalan, Sumie Kato, Isidora Solar, Claudia Arancibia. B62 Discoidin domain receptor 2 (DDR2) modulates invasion and metastasis via epithelial mesenchymal transition in ovarian cancer. Laura Divine, Whitney Grither, Eric Meller, Anne Gibson, Andrew Loza, Riva Desai, Gregory Longmore, Katherine Fuh. B63 Expression of VEGF in ovarian cancer suppresses tumor immunity through recruitment of myeloid derived suppressor cells. Naoki Horikawa, Kaoru Abiko, Noriomi Matsumura , Junzo Hamanishi, Susan Murphy, Tsukasa Baba, Ken Yamaguchi, Masafumi Koshiyama, Ikuo Konishi. B64 Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Zhenqiu Liu, Jessica A Beach, Hasmik Agadjanian, Dongyu Jia, Paul-Joseph Aspuria, Beth Y Karlan, Sandra Orsulic. B65, PR17 Characterization of ascites and tumor derived ovarian cancer stem-like cells. Katja Kaipio, Ping Chen, Kaisa Huhtinen, Piia Mikkonen, Paivi Ostling, John Patrick Mpindi, Laura Lehtinen, Pia Roering, Taina Korpela, Krister Wennerberg, Bhagwan Yadav, Tero Aittokallio, Evgeny Kulesskiy, Johanna Hynninen, Annika Auranen, Seija Grénman, Sampsa Hautaniemi, Olli Carpén.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.

B66 Blockade of PD-1 signaling in tumor-associated dendritic cells results in compensatory IL-10 release maintaining immune suppression in ovarian cancer microenvironments. Purushottam Lamichhane, Lavakumar Karyampudi, Barath Shreeder, James Krempski, Deborah Bahr, Matthew Block, Keith Knutson. B67 The impact of parity on the metastatic success of ovarian cancer. Elizabeth A Loughran, Ryan Phan, Annemarie K Leonard , Laura Tarwater, Marwa Asem, Yuliya Klymenko, Yueying Liu, Jing Yang, Jeff Johnson, Matthew Ravosa, M. Sharon Stack. B68 Erythropoietin stimulates ovarian tumor growth via EphB4. Sunila Pradeep, Jie Huang, Edna Mora, Sherry Y Wu, Chun Li, Gabriel Lopez-Berestein, David Jackson, Anil Sood. B69 Notch3 signal activation promotes peritoneal metastasis in a mouse model of epithelial ovarian cancer. Jessica Price, Elham Azizi, Nathaniel Jones, Jan Kitajewski. B70 Targeted activation of macrophages to limit ovarian cancer progression. Whitney Barham, Andrew Wilson, Ryan Ortega, Jeanette Saskowski, Oleg Tikhomirov, Todd Giorgio, Dineo Khabele, Fiona E Yull.

Other B71 Old age and chemotherapy contribute to the selection of PPM1D somatic mosaic mutations in ovarian cancer. Maria I. Harrell, Barbara M. Norquist, Tom Walsh, Mark F. Brady, Ming K. Lee, Robert Hershberg, Kimberly R. Kalli, Heather Lankes, Eric Q. Konnick, Colin C. Pritchard, Bradley J. Monk, John K. Chan, Robert Burger, Scott H. Kaufmann, Michael J. Birrer, Elizabeth M. Swisher.

Immunotherapy for Ovarian Cancer B72 Long-term survival and outcome update on patients (pts) with recurrent ovarian cancer who received ipilimumab post GVAX vaccine. Ursula Anne Matulonis, Stephen Hodi , Glenn Dranoff , Susana Campos, Richard Penson, Robert Soiffer, Marcus Butler.

Other B73 The monoterpene, citral, increases intracellular oxygen radicals and inhibits cancer cell proliferation by inducing apoptosis and endoplasmic reticulum stress. Arvinder Kapur, Mildred Felder, Lucas Fass, Justanjyot kaur, Austin Czarnecki, Kavya Rathi, Manish Patankar.

An AACR Special Conference on

Advances in Ovarian Cancer Research: Exploiting Vulnerabilities October 17-20, 2015 • Hyatt Regency • Orlando, FL Poster Session B – Monday, October 19, 2015, 12:45 p.m.-3:30 p.m.

B74 Can we repurpose anti-malarial drug quinacrine to treat ovarian cancer? Debarshi Roy, Ashwani Khurana, Eleftheria Kalogera, Xuyang Wen, Susmita Mondal, Viji Shridhar. B75 Increased basal autophagy decreases sensitivity to cisplatin in chemoresistant ovarian cancer. Thomas R. Silvers, Peter R. Dottino, John A. Martignetti, Brad R. Evans. B76 Involuntary weight loss is an independent prognostic factor for overall survival and predicts better response to chemotherapy in high-grade serous ovarian cancer patients. j Jan Sznurkowski, Maciej Pawlowski, Pawel Kabata. B77 Examining selection for resistant clones in high-grade serous ovarian cancer after neoadjuvant chemotherapy. Alicia Tone, Jocelyn Stewart, Carl Virtanen, Marcus Bernardini, Stephane Laframboise, Sarah Ferguson, Amit Oza, Theodore Brown, Taymaa May. B78 Differential methylation of HIST1H2BB and MAGI2 in ovarian cancers. Blanca L Valle, Elisabetta Kuhn, David Sidransky, Rafael Guerrero-Preston. B79 Translational study of tumor treating fields in combination with paclitaxel in ovarian cancer. Mijal Munster, Roni Blat, Paul C Roberts, Eva M Schmelz, Moshe Giladi, Rosa S Schneiderman, Yaara Porat, Zeev Bomzon, Noa Urman, Aviran Itzhaki, Tali Voloshin, Shay Cahal, Eilon D Kirson, Uri Weinberg, Yoram Palti . B80 Tumor expression subtypes of high-grade serous ovarian cancer demonstrate associations with likelihood of complete resection: a single-center study. Chen Wang, Jamie Bakkum-Gamez, Andrea Mariani, William Cliby, Ellen Goode.

Molecular Drivers of Ovarian Cancer (other than p53) B81 The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to the cyclin-dependent kinase 2 inhibitor dinaciclib. Andrew J Wilson, Jeanette Saskowski, Dineo Khabele.

Other B82 Application of modulated electro-hyperthermia for the cellular target therapy in ovarian cancer cells. Wookyeom Yang, Doo Byung Chay, Hanbyoul Cho, Sunghoon Kim, Jinkyoung Kong, Geumseon Son, Jihui Choi, Kim Jae-hoon.